NUWE Stock Analysis: Buy, Sell, or Hold?
NUWE - Nuwellis, Inc. Common Stock
$0.09
-0.04 (-33.13%)
▼
5d:
-36.59%
30d:
-91.85%
90d:
-92.22%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When NUWE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NUWE is down 36.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NUWE is down 36.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NUWE is currently trading at $0.09, which is considered oversold relative to its 30-day fair value range of $0.11 to $0.83.
Technical Outlook: Technically, NUWE is in a downtrend. The price is currently testing key support at $0.13. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 33.1% recently.
Market Sentiment: NUWE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+8493.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUWE is in a downtrend. The price is currently testing key support at $0.13. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 33.1% recently.
Market Sentiment: NUWE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+8493.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.11 -
$0.83
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-33.1%)
- BULLISH: Trading 8493.8% below Wall St target ($11.00)
- WARNING: Recommendation downgraded due to -36.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.11 -
$0.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.13
Resistance Level
$0.99
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.20
Wall Street Target
$11.00
(+8493.8%)
Revenue Growth (YoY)
26.2%
Earnings Growth (YoY)
-99.2%
Profit Margin
-217.2%
Share & Embed Analysis
Last updated: June 24, 2026 2:11 PM ET
Data refreshes hourly during market hours. Next update: 3:11 PM
Data refreshes hourly during market hours. Next update: 3:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUWE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 67 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 65 BUY |
